| 2001-2004 | 2005-2006 | 2007-2008 | 2009-2011 | P value |
---|---|---|---|---|---|
N (1066) | 285 | 265 | 306 | 210 | -- |
Time between symptom onset and 1st PRh, weeks | 22.7 (11.9, 40.1) | 23.5 (12.1, 52.7) | 24.7 (12, 58.2) | 23.1 (13.2, 50.1) | 0.28 |
% seen within 10 weeks | 20.5% | 21% | 20% | 19% | 0.66 |
Time from referral to 1st PRh appointment, weeks | 3.4 (1.2, 7.9) | 4 (1.4, 7.3) | 4.7 (1.4, 8) | 4.3 (1.6, 8.7) | 0.61 |
% seen within 4 weeks | 58% | 55% | 49% | 50% | 0.02 |
AJC | 2 (1, 4) | 2 (1, 6) | 2 (1, 5) | 2 (1, 5) | 0.82 |
JADAS | 10.8 (7, 16.2) | 12.1 (7.2, 20.2) | 9.3 (4.4, 18.4) | 10.4 (4, 10.6) | 0.60 |
CHAQ | 0.8 (0.1, 1.5) | 0.9 (0.3, 1.5) | 0.6 (0.1, 1.4) | 0.6 (0.1, 1.3) | 0.045 |
Oligoarticular pattern: Time (days) from 1st PRh to 1st IA steroid, median (IQR) | 25.5 (9,65) | 25 (7, 49) | 19 (8, 48) | 19 (9, 48) | 0.04 |
% in MDA at 1 year | 62 | 66 | 66 | 67 | 0.87 |
Time (days) from 1st PRh to 1st methotrexate, median (IQR) | 27 (1, 79) | 17 (1, 43) | 5 (0, 17) | 11 (0, 84) | 0.03 |
% in MDA at 1 year | 39 | 56 | 50 | 59 | 0.07 |
Time (days) from 1st PRh to 1st methotrexate, median (IQR) | 37 (14, 78) | 14 (9, 25) | 15 (6, 24) | 15 (13, 26) | 0.07 |
% in MDA at 1 year | 64 | 50 | 75 | 57 | 0.85 |